{
    "nctId": "NCT00191789",
    "briefTitle": "Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer",
    "officialTitle": "Neoadjuvant Administration of Gemcitabine Plus Doxorubicin Followed by Gemcitabine Plus Cisplatin in Large or Locally Advanced Operable Breast Cancer: A Phase II Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 65,
    "primaryOutcomeMeasure": "Number of Patients With Pathological Complete Response (Pathological Complete Response Rate)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of breast carcinoma\n* No previous chemotherapy, with bidimensionally measurable locally advanced disease\n* Adequate performance status (Karnofsky Performance Status \\[KPS\\] greater than or equal to 70), bone marrow reserves, hepatic, cardiac and renal functions.\n\nExclusion Criteria:\n\n* Inflammatory breast cancer\n* Pregnancy and Breast-feeding\n* Serious concomitant disorder or infection\n* Previous cancer within the last 5 years or a second primary malignancy.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}